During the past decade, Centro de Investigación Cardiometabólica de Aguascalientes conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 7 clinical trials were completed, i.e. on average, 87.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 5 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Investigación Cardiometabólica de Aguascalientes" #1 sponsor was "Allergan" with 3 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Pfizer" with 2 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored and "Kowa Research Institute, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Investigación Cardiometabólica de Aguascalientes" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Investigación Cardiometabólica de Aguascalientes" are "Diabetes Mellitus" (3 trials), "Gastroparesis" (3 trials), "Diabetes Mellitus, Type 2" (2 trials), "Cardiovascular Disease" (1 trials) and "Chronic Kidney Disease" (1 trials). Many other conditions were trialed in "Centro de Investigación Cardiometabólica de Aguascalientes" in a lesser frequency.

Most popular intervention types in "Centro de Investigación Cardiometabólica de Aguascalientes" are "Drug" (11 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Relamorelin" (3 trials), "Alogliptin Benzoate" (1 trials), "BI 685509" (1 trials) and "BI 690517" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Investigación Cardiometabólica de Aguascalientes" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Centro de Investigación Cardiometabólica de Aguascalientes". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Centro de Investigación Cardiometabólica de Aguascalientes, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Investigación Cardiometabólica de Aguascalientes, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".